Vestal Point Capital LP Grows Stock Holdings in Immatics (NASDAQ:IMTX)

Vestal Point Capital LP lifted its stake in Immatics (NASDAQ:IMTX - Free Report) by 67.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,275,000 shares of the company's stock after acquiring an additional 2,525,000 shares during the quarter. Immatics accounts for about 2.6% of Vestal Point Capital LP's investment portfolio, making the stock its 13th largest holding. Vestal Point Capital LP owned 5.26% of Immatics worth $44,615,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. abrdn plc grew its stake in shares of Immatics by 49.2% in the fourth quarter. abrdn plc now owns 347,379 shares of the company's stock worth $2,470,000 after acquiring an additional 114,479 shares during the period. Guggenheim Capital LLC bought a new stake in Immatics during the fourth quarter valued at approximately $101,000. Marshall Wace LLP bought a new stake in Immatics during the fourth quarter valued at approximately $409,000. Y Intercept Hong Kong Ltd bought a new stake in Immatics during the fourth quarter valued at approximately $211,000. Finally, Schroder Investment Management Group grew its position in Immatics by 52.6% during the fourth quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock valued at $2,953,000 after buying an additional 147,547 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Down 1.7%

NASDAQ:IMTX traded down $0.09 during trading hours on Friday, hitting $5.11. 375,092 shares of the stock traded hands, compared to its average volume of 659,209. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77. The company has a market cap of $621.12 million, a price-to-earnings ratio of -7.74 and a beta of 0.87. The stock has a 50 day moving average price of $4.52 and a 200 day moving average price of $5.73.

Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The firm had revenue of $20.12 million for the quarter, compared to the consensus estimate of $14.92 million. Equities analysts forecast that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IMTX has been the subject of several recent research reports. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday. Cantor Fitzgerald restated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $17.00.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.